Compare · FLAG vs MRNA
FLAG vs MRNA
Side-by-side comparison of First Light Acquisition Group Inc. (FLAG) and Moderna Inc. (MRNA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both FLAG and MRNA operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- MRNA is the larger of the two at $21.75B, about 77.0x FLAG ($282.6M).
- Over the past year, FLAG is up 0.0% and MRNA is up 98.4% - MRNA leads by 98.4 points.
- MRNA has hit the wire 6 times in the past 4 weeks while FLAG has been quiet.
- MRNA has more recent analyst coverage (25 ratings vs 0 for FLAG).
- Company
- First Light Acquisition Group Inc.
- Moderna Inc.
- Price
- $27.42+268.55%
- $54.84-5.30%
- Market cap
- $282.6M
- $21.75B
- 1M return
- +0.00%
- -24.35%
- 1Y return
- +0.00%
- +98.41%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- 2018
- News (4w)
- 0
- 6
- Recent ratings
- 0
- 25
First Light Acquisition Group Inc.
First Light Acquisition Group, Inc. does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses or entities. The company was incorporated in 2021 and is headquartered in Reston, Virginia.
Moderna Inc.
Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. As of March 9, 2021, the company had 13 programs in clinical trials and a total of 24 development programs in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted and cell surface therapeutics, and systemic intracellular therapeutics. The company has strategic alliances with AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, the Biomedical Advanced Research and Development Authority, the Defense Advanced Research Projects Agency, the National Institute of Allergy and Infectious Diseases, the National Institutes of Health, the Coalition for Epidemic Preparedness Innovations, and Bill & Melinda Gates Foundation. Moderna, Inc. also has collaborations with Lonza Ltd. for the manufacture of COVID-19 vaccine; and Catalent Inc., Laboratorios Farmacéuticos Rovi, S.A., Recipharm, and Lonza Group for fill-finish manufacturing of its COVID-19 vaccine candidate, as well as Aldevron, LLC for supporting COVID-19 vaccine and additional programs in company's clinical development pipeline. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Latest FLAG
- SEC Form SC 13G/A filed by First Light Acquisition Group Inc. (Amendment)
- SEC Form SC 13G/A filed by First Light Acquisition Group Inc. (Amendment)
- SEC Form SC 13G/A filed by First Light Acquisition Group Inc. (Amendment)
- SEC Form SC 13G/A filed by First Light Acquisition Group Inc. (Amendment)
- First Light Acquisition Group Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits
- SEC Form 424B3 filed by First Light Acquisition Group Inc.
- SEC Form SC 13G/A filed by First Light Acquisition Group Inc. (Amendment)
- SEC Form SC 13G/A filed by First Light Acquisition Group Inc. (Amendment)
- First Light Acquisition Group Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure
- SEC Form S-1/A filed by First Light Acquisition Group Inc. (Amendment)
Latest MRNA
- SEC Form 10-Q filed by Moderna Inc.
- Moderna Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Moderna Reports Second Quarter 2026 Financial Results and Provides Business Updates
- Amendment: SEC Form SCHEDULE 13G/A filed by Moderna Inc.
- President Hoge Stephen exercised 53,336 shares at a strike of $19.15 and sold $3,605,514 worth of shares (53,336 units at $67.60) as part of a pre-agreed trading plan (SEC Form 4)
- Moderna Announces First Participant Dosed in Phase 1 Clinical Trial Evaluating Investigational Tumor-Targeted Cancer Antigen Therapy in Solid Tumors
- SEC Form 4 filed by Director Mcdonnell Michael R.
- SEC Form 3 filed by new insider Mcdonnell Michael R.
- Moderna to Report Second Quarter 2026 Financial Results on Friday, July 31, 2026
- Moderna Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits